P

Protagenic Therapeutics, Inc. (PTIX)

OQB – Real vaqt narxi. Valyuta: USD

0.48

-0.17 (-25.54%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

P

Protagenic Therapeutics, Inc. (PTIX)

OQB – Real vaqt narxi. Valyuta: USD

0.48

-0.17 (-25.54%)

Yopilishda: May 12, 2026, 4:00 PM EDT

23.04.2026

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related neuropsychiatric disorders, today announced the appointment of Bill Nichols Jr. as President. This strategic leadership addition, combined with a thoughtful optimization of the Company's management structure, sharpens focus and resources on advancing its lead candidate, PT00114 - positioning Protagenic for accelerated clinical progress and long-term value creation for patients and shareholders alike.

17.03.2026

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW YORK CITY, NY / ACCESS Newswire / March 17, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related neuropsychiatric disorders, today announced the closing of a settlement and separation related to its prior Phytanix Bio acquisition. The transaction simplifies Protagenic's capital structure, materially reducing liabilities and sharpens the Company's operating focus on PT00114.

10.03.2026

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related disorders, including treatment-resistant depression and anxiety, today announced that its common stock has been upgraded from OTC Pink to the OTCQB® and has commenced trading on OTCQB under the symbol "PTIX." The OTCQB is a recognized public market for developing companies that meet defined reporting, management certification and bid price standards.

09.12.2025

Results from Phase 1 Multiple-Dose Study of PT00114

Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing therapeutics that target the biology of chronic stress and its downstream psychiatric and neurologic effects, today reported positive topline safety results from its Phase 1 Multiple Dose (MD) study of PT00114. PT00114 is a synthetic analogue of a naturally occurring brain peptide thought to be involved in restoring homeostasis following prolonged exposure to stress.

27.11.2025

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications Staff (the "Staff") indicating that the Company is not in compliance with Nasdaq Listing Rules 5550(b)(1) (minimum stockholders' equity) and 5250(c)(1) (timely filing of periodic reports). The Staff determined that, based on the stockholders' equity reported in the Company's Transition Report on Form 10-QT for the period ended June 30, 2025, the Company no longer satisfies the minimum $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1).

13.11.2025

Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study

NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and neurodegenerative disorders, today announced the successful completion of enrollment and dosing in its Multiple Ascending Dose (MAD) Phase 1 study evaluating its lead compound, known as PT00114. The study, conducted in healthy volunteers, was designed to assess the safety and tolerability profile of PT00114 following multiple doses over time.

30.07.2025

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.

Videolar

No Data

There is no data to display

Press-relizlar

23.04.2026

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related neuropsychiatric disorders, today announced the appointment of Bill Nichols Jr. as President. This strategic leadership addition, combined with a thoughtful optimization of the Company's management structure, sharpens focus and resources on advancing its lead candidate, PT00114 - positioning Protagenic for accelerated clinical progress and long-term value creation for patients and shareholders alike.

17.03.2026

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW YORK CITY, NY / ACCESS Newswire / March 17, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related neuropsychiatric disorders, today announced the closing of a settlement and separation related to its prior Phytanix Bio acquisition. The transaction simplifies Protagenic's capital structure, materially reducing liabilities and sharpens the Company's operating focus on PT00114.

10.03.2026

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related disorders, including treatment-resistant depression and anxiety, today announced that its common stock has been upgraded from OTC Pink to the OTCQB® and has commenced trading on OTCQB under the symbol "PTIX." The OTCQB is a recognized public market for developing companies that meet defined reporting, management certification and bid price standards.

09.12.2025

Results from Phase 1 Multiple-Dose Study of PT00114

Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing therapeutics that target the biology of chronic stress and its downstream psychiatric and neurologic effects, today reported positive topline safety results from its Phase 1 Multiple Dose (MD) study of PT00114. PT00114 is a synthetic analogue of a naturally occurring brain peptide thought to be involved in restoring homeostasis following prolonged exposure to stress.

Search stocks

Protagenic Therapeutics, Inc. (PTIX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Protagenic Therapeutics, Inc. (PTIX)

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

Results from Phase 1 Multiple-Dose Study of PT00114

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

Videolar

No Data

Press-relizlar

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

Results from Phase 1 Multiple-Dose Study of PT00114